Advancing Knowledge. Enhancing Care.
Advancing Knowledge. Enhancing Care.

Psoriasis News

the latest news from ipc, industry and others

Displaying 1 to 2 of 64 Posts . Displaying 2 of Posts . Page of 32 . Go To Page: . Per Page: . . . View All Sort By: .

Lilly's Taltz® (ixekizumab) Receives U.S. FDA Approval for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis

Lilly's TALTZ® (IXEKIZUMAB) receives U.S. FDA approval for the treatment of pediatric patients with moderate to severe plaque psoriasis

Read More

Statement on the Coronavirus (COVID-19) Outbreak

For psoriasis patients diagnosed with COVID-19 disease, the IPC recommends physicians discontinue or postpone use of immunosuppressant medications. This is in accordance with established psoriasis treatment guidelines, which state immunosuppressive psoriasis treatments are contraindicated in patients with active infections.

Read More
UPCOMING EVENT

Biomarkers in psoriasis and psoriatic arthritis: moving toward personalized therapy

Wednesday, May 13, 2020
9:00 am – 12:00 pm
Scottsdale, Arizona
Registration opening soon

Stay informed

Join the email list to receive the latest information on psoriasis meetings, manuscripts and research.
SUBSCRIBE

We use cookies on this website to enhance your experience. By continuing with this website, you consent to our use of cookies. Learn more.
OK